Obstructive sleep apnea (OSA) prevalence peaks at age 55, with patients experiencing frequent cardiovascular comorbidities, including hypertension and diabetes, per study of 556,474 US patients with OSA

A personalized approach to recommending CPAP machines for patients with obstructive sleep apnea (OSA) may decrease adverse cardiovascular events. However, CPAP use can also increase cardiovascular risk for those with low-risk OSA markers.

A comprehensive review identifies exosomes as critical mediators in the process of obstructive sleep apnea (OSA)-related diseases. OSA-induced intermittent hypoxia and sleep fragmentation alter exosome secretion and content, disrupting cell function and leading to various comorbidities.

Researchers at Mount Sinai are developing an AI-based predictive tool that can analyze complex sleep study data to predict cardiovascular event risk and treatment response among individuals with obstructive sleep apnea. The findings could help clinicians make more informed recommendations about OSA treatment for their patients.

Researchers have developed a novel drug therapy for obstructive sleep apnea (OSA), which has shown significant improvements in reducing breathing interruptions and improving overall health. The treatment targets both respiratory and metabolic complications, providing a promising alternative to existing therapies.

Researchers evaluated 12 hypnotic medications on sleep architecture and respiratory function in adults with obstructive sleep apnea. The study found that while some medications worsened respiratory outcomes, others showed no significant effects, highlighting the need for individualized treatment.

A new study found that women with moderate-to-severe obstructive sleep apnea reported worse symptoms, including sleep disturbance, fatigue, anxiety, and cognitive function, compared to men. The study suggests that current algorithms for diagnosing and treating sleep apnea may not consider the broader range of symptoms women experience.